Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced new share option grants under its Long-Term Incentive Plan (LTIP) and staff share option plans. The company approved 12 million LTIP Options for executive directors and up to 13.8 million Staff Share Options.
The allocation considers that no bonuses were awarded for three consecutive years to conserve cash. The Staff Share Options are priced at 10.00 pence per share, 2.6% above the closing price of 9.75 pence on March 20, 2025. Following these grants, ANGLE will have outstanding options over 51,369,480 Ordinary Shares, representing 13.7% of issued capital, within the approved 16% limit.
The LTIP Options include a three-year performance period plus a two-year holding period, with performance conditions linked to share price CAGR above the June 2024 funding round price of 15.00 pence per share.
ANGLE plc (ANPCY) has announced successful completion of key development projects with AstraZeneca and Eisai. The company has developed two assays for AstraZeneca: a prostate cancer androgen receptor (AR) assay and a multi-cancer DDR micronuclei assay for DNA damage detection in CTCs.
The AR therapeutic market is projected to reach $9.2 billion by 2033, with over 46,000 patients in 181 clinical studies. The DDR therapeutic market, valued at $8.2 billion in 2024, is expected to grow to $30.3 billion in the next decade.
Additionally, ANGLE's Parsortix-based HER2 assay demonstrated successful results in Eisai's Phase 2 pilot study for breast cancer patients, showing the ability to measure HER2 status changes over time. The HER2 therapeutic market, valued at $9.4 billion in 2023, is projected to reach $13.2 billion by 2030.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced successful results from its dual analysis of circulating tumor DNA (ctDNA) and CTC-DNA using Illumina's technology platform. The study, conducted on 27 lung cancer patients, demonstrated that 100% of untreated patients and 90% of treated patients had cancer mutations identified exclusively in CTC-DNA, not found in ctDNA from the same blood sample.
The research utilized Illumina's customized 79-gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform. The dual analysis approach found twice as many mutations compared to single-analyte testing, potentially providing more comprehensive biomarkers for treatment guidance.
Following these positive results, ANGLE has been invited to present their findings at an EACR-Illumina webinar on February 6, 2025. This marks the first joint marketing initiative between ANGLE and Illumina, whose NGS systems are installed across more than 9,500 customers in 155 countries.
ANGLE plc has announced breakthrough research from ETH Zurich published in Nature Medicine, featuring their Parsortix system in a Phase 1 clinical trial for metastatic breast cancer treatment. The study used FDA-approved drug digoxin and demonstrated the Parsortix system's critical role in identifying patients with CTC clusters for targeted treatment.
The trial achieved its primary endpoint, showing significant reduction in CTC cluster size in the treatment group. This proof-of-principle study opens possibilities for developing novel drugs preventing metastasis. Professor Aceto's lab has co-founded PAGE Therapeutics to develop compounds effective at disassociating CTC clusters, with Parsortix expected to play a important role in future development.
The research is particularly significant as metastasis accounts for the majority of cancer-related deaths. The Parsortix system's unique ability to capture CTC clusters makes it valuable for developing drugs targeting metastatic spread, potentially improving patient outcomes across all solid tumors.
ANGLE plc (AIM:AGL, OTCQX:ANPCY), a liquid biopsy company, released its trading update for FY2024. Revenue increased 31% to £2.9 million (from £2.2 million in FY23). The company maintains a strong cash position of £10.4 million as of December 31, 2024, with expected R&D tax credits of £1.4 million in Q1 2025 and £0.8 million in Q3 2025, totaling available cash resources of £12.6 million.
The company's annual loss decreased 30% to approximately £14 million (from £20.1 million in FY23), aligning with guidance. Following strategic focus on pharma services and cost reduction, current cash reserves provide runway into 2026. The company expects higher revenue growth in 2025 compared to 2024, with potential for significant increase over time, supported by progressing pharma contracts and new opportunities.
ANGLE plc announced the presentation of an independent study by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, showcasing a novel Parsortix-based HER2 workflow. The study, involving 16 metastatic breast cancer patients, demonstrated 100% success in isolating CTCs and classifying their HER2 status. The research identified patients with HER2-expressing CTCs who had HER2-negative tissue biopsies, suggesting potential for expanded treatment options.
The workflow enables quantitative and semi-automated assessment of HER2 in CTCs, which is important as HER2 status can change in up to 38% of breast cancer patients. This development could help identify patients eligible for HER2-targeted antibody drug conjugates (ADCs), particularly beneficial for the over 60% of breast cancer patients initially diagnosed as HER2-negative.
ANGLE plc has presented new data at the AACR Special Conference showcasing their Parsortix-based PD-L1 assay for lung cancer monitoring. The assay demonstrated high analytical sensitivity and specificity in identifying different CTC phenotypes and determining PD-L1 status. In a study of metastatic lung cancer patients, CTCs were identified in 91% of cases, with PD-L1 positive CTCs found in 72% of patients with PD-L1 positive tissue biopsies and 27% of those with negative biopsies. The technology enables minimally invasive, longitudinal monitoring of PD-L1 status, potentially advancing personalized treatment approaches.
ANGLE plc presented new data at the AACR Special Conference regarding their development of a Parsortix-based HER2 assay kit in collaboration with BioView. The study, involving 43 metastatic breast cancer patients, showcased a scoring system for HER2 expression in circulating tumor cells (CTCs). The research demonstrated that some initially HER2-negative patients became HER2-positive over time, as detected through CTC analysis. This blood-based test could enable identification of patients who might benefit from HER2-targeted therapies, particularly important since approximately 80% of breast cancer patients are initially categorized as HER2-negative, but their status can change over time.